Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Hemophilia Market

Hemophilia Market Size, Share & Trends Analysis Report, By Product Type (Clotting Factor Replacement Therapy, Extended Half-Life (EHL) Factor Products, Non-Factor Replacement Therapy, Gene Therapy), By Technology Platform (Recombinant DNA Technology, Plasma Fractionation Technology, Fc Fusion / PEGylation, RNA Interference (RNAi), Gene Transfer (AAV Vectors)), By End User (Hospitals & Hemophilia Treatment Centers (HTCs), Specialty Clinics, Homecare Settings), Forecast Period (2026-2035)

Published: Jun 2026 | Report Code: OMR2029829 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Hemophilia market size was valued at $13.11 billion in 2025 and is projected to reach $20.45 billion by 2035, growing at a CAGR of 4.5% between 2026 and 2035. The market includes therapies used to manage a rare genetic bleeding disorder characterized by deficiency of clotting factors. A key driver supporting market growth is the increasing prevalence and diagnosis of rare bleeding disorders. According to the World Health Organization, hemophilia affects thousands of individuals globally, with improved diagnosis rates increasing treatment demand. Additionally, advancements in biologics and gene therapy are accelerating innovation in the market. Regulatory support from agencies such as the U.S. Food and Drug Administration is facilitating faster approvals of novel therapies. The growing adoption of homecare treatment and self-administration technologies is further contributing to market expansion.

Market Dynamics

Rising Prevalence of Rare Bleeding Disorders Driving Market Growth

The increasing prevalence of hemophilia and other bleeding disorders is a major factor driving market growth. According to the World Health Organization, rare diseases collectively affect a significant global population, increasing healthcare demand. Growing awareness, screening programs, and improved healthcare access are contributing to higher diagnosis rates. Pharmaceutical companies are investing heavily in biologics, recombinant therapies, and gene therapies between 2024 and 2026 to enhance treatment outcomes. Additionally, support from organizations such as European Federation of Pharmaceutical Industries and Associations highlights increasing R&D investment in rare disease therapeutics, driving continuous innovation.

High Treatment Costs and Complex Manufacturing Limiting Market Growth

Despite strong growth potential, the hemophilia market faces challenges related to high treatment costs and complex production processes. Advanced therapies such as gene therapy and recombinant biologics require significant investment in R&D and manufacturing infrastructure. Additionally, regulatory approval processes are complex and time-consuming, increasing development timelines. Limited accessibility in developing regions due to cost constraints further restricts market penetration. Companies are addressing these challenges by investing in cost-effective production technologies, expanding manufacturing capacity, and forming strategic collaborations to improve global accessibility.

Market Segmentation

  • Based on the product type, the market is segmented into clotting factor replacement therapy, extended half-life (EHL) factor products, non-factor replacement therapy, and gene therapy.
  • Based on the technology platform, the market is segmented into recombinant DNA technology, plasma fractionation technology, Fc fusion / PEGylation, RNA interference (RNAi), and gene transfer (AAV vectors).
  • Based on the end user, the market is segmented into hospitals & hemophilia treatment centers (HTCs), specialty clinics, and homecare settings.

Clotting Factor Replacement Therapy Segment Leads the Market

The clotting factor replacement therapy segment holds a dominant position due to its widespread clinical use and established efficacy. These therapies remain the primary treatment option for managing bleeding episodes. Pharmaceutical companies have focused on improving safety and reducing immunogenicity between 2022 and 2026. The availability of both plasma-derived and recombinant products further supports its dominance. Additionally, strong clinical evidence and established treatment protocols continue to drive adoption globally.

Gene Therapy Segment to Record Strong Growth

The gene therapy segment is expected to witness strong growth due to advancements in genetic engineering and precision medicine. Gene therapies offer the potential for long-term or curative treatment, significantly reducing treatment burden. Increasing investments in biotechnology and collaborations between pharmaceutical companies and research institutions are accelerating innovation. The growing focus on personalized medicine is further driving adoption of gene therapy in the hemophilia market.

Regional Outlook

The global Hemophilia market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the hemophilia market due to advanced healthcare infrastructure and high adoption of innovative therapies. According to the U.S. Food and Drug Administration, increasing approvals of biologics and gene therapies are supporting market growth. Strong R&D investment and early adoption of advanced therapies further enhance market expansion.

China to Record Strong Growth

China is expected to witness strong growth due to increasing healthcare investments and rising awareness of rare diseases. According to the World Health Organization, improving healthcare infrastructure and government initiatives are supporting diagnosis and treatment accessibility. Expanding pharmaceutical manufacturing capabilities further drive market growth.

Competitive Landscape

The hemophilia market is highly competitive, with companies focusing on innovation and strategic collaborations. Key players such as Genentech, Takeda Pharmaceuticals, Novo Nordisk, Sanofi, and CSL Behring are investing in advanced therapeutics, including gene therapy and non-factor therapies. These companies are also expanding their global presence and strengthening supply chains to enhance market positioning.

Recent Developments

  • In March 2026, Pfizer Inc. received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for HYMPAVZI (marstacimab) as a once-weekly subcutaneous treatment for adults and adolescents with hemophilia A or B with inhibitors. The recommendation supports expansion of its indication in the European Union, bringing the therapy closer to approval and offering a convenient treatment option without routine laboratory monitoring. This development strengthens Pfizer’s position in non-factor hemophilia therapies while addressing unmet needs in patients with inhibitors, who often experience limited treatment effectiveness with traditional therapies.
  • In February 2025, Pfizer Inc. announced the discontinuation of its hemophilia B gene therapy Beqvez (fidanacogene elaparvovec) globally, ending further development and commercialization activities. The decision was driven by limited patient and physician demand for gene therapies, along with market adoption challenges despite recent regulatory approval. This move reflects a strategic shift in Pfizer’s portfolio toward more commercially viable therapies, while highlighting ongoing barriers in gene therapy adoption such as high costs and complex treatment pathways.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global hemophilia market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Hemophilia Market Sales Analysis – Product Type | Technology Platform | End User ($ Million)
  • Hemophilia Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Hemophilia Market Trends
2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Hemophilia Market

2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Hemophilia Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Hemophilia Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Hemophilia Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Hemophilia Market Revenue and Share by Manufacturers

  • Hemophilia Product Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 Genentech
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy

4.2.2 Takeda Pharmaceuticals
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy

4.2.3 Novo Nordisk
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy

4.2.4 Sanofi
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy

4.2.5 CSL Behring
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration

  1. Global Hemophilia Market Sales Analysis by Product Type ($ Million)

5.1 Clotting Factor Replacement Therapy
5.2 Extended Half-Life (EHL) Factor Products
5.3 Non-Factor Replacement Therapy
5.4 Gene Therapy

  1. Global Hemophilia Market Sales Analysis by Technology Platform ($ Million)

6.1 Recombinant DNA Technology
6.2 Plasma Fractionation Technology
6.3 Fc Fusion / PEGylation (Half-life extension)
6.4 RNA Interference (RNAi)
6.5 Gene Transfer (AAV Vectors)

  1. Global Hemophilia Market Sales Analysis by End User ($ Million)

7.1 Hospitals & Hemophilia Treatment Centers (HTCs)
7.2 Specialty Clinics
7.3 Homecare Settings

  1. Regional Analysis

8.1 North American Hemophilia Market Sales Analysis – Product Type | Technology Platform | End User ($ Million)

8.1.1 United States
8.1.2 Canada

8.2 European Hemophilia Market Sales Analysis – Product Type | Technology Platform | End User ($ Million)

8.2.1 UK
8.2.2 Germany
8.2.3 Italy
8.2.4 Spain
8.2.5 France
8.2.6 Russia
8.2.7 Rest of Europe

8.3 Asia-Pacific Hemophilia Market Sales Analysis – Product Type | Technology Platform | End User ($ Million)

8.3.1 China
8.3.2 Japan
8.3.3 South Korea
8.3.4 India
8.3.5 Australia & New Zealand
8.3.6 ASEAN Countries
8.3.7 Rest of Asia-Pacific

8.4 Rest of the World Hemophilia Market Sales Analysis – Product Type | Technology Platform | End User ($ Million)

8.4.1 Latin America
8.4.2 Middle East and Africa

  1. Company Profiles

9.1 Alnylam Pharmaceuticals
9.1.1 Quick Facts
9.1.2 Company Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies

9.2 Bayer
9.2.1 Quick Facts
9.2.2 Company Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies

9.3 BioMarin Pharmaceutical
9.3.1 Quick Facts
9.3.2 Company Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies

9.4 Biotest AG
9.4.1 Quick Facts
9.4.2 Company Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies

9.5 Centessa Pharmaceuticals
9.5.1 Quick Facts
9.5.2 Company Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies

9.6 Emergent BioSolutions
9.6.1 Quick Facts
9.6.2 Company Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies

9.7 GC Biopharma
9.7.1 Quick Facts
9.7.2 Company Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies

9.8 Grifols
9.8.1 Quick Facts
9.8.2 Company Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies

9.9 HEMA Biologics
9.9.1 Quick Facts
9.9.2 Company Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies

9.10 Kamada Pharmaceuticals
9.10.1 Quick Facts
9.10.2 Company Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies

9.11 Kedrion Biopharma
9.11.1 Quick Facts
9.11.2 Company Overview
9.11.3 Product Portfolio
9.11.4 Business Strategies

9.12 LFB Group
9.12.1 Quick Facts
9.12.2 Company Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies

9.13 Octapharma AG
9.13.1 Quick Facts
9.13.2 Company Overview
9.13.3 Product Portfolio
9.13.4 Business Strategies

9.14 Pfizer
9.14.1 Quick Facts
9.14.2 Company Overview
9.14.3 Product Portfolio
9.14.4 Business Strategies

9.15 Regeneron Pharmaceuticals
9.15.1 Quick Facts
9.15.2 Company Overview
9.15.3 Product Portfolio
9.15.4 Business Strategies

9.16 Sangamo Therapeutics
9.16.1 Quick Facts
9.16.2 Company Overview
9.16.3 Product Portfolio
9.16.4 Business Strategies

9.17 SK Plasma
9.17.1 Quick Facts
9.17.2 Company Overview
9.17.3 Product Portfolio
9.17.4 Business Strategies

9.18 Sobi
9.18.1 Quick Facts
9.18.2 Company Overview
9.18.3 Product Portfolio
9.18.4 Business Strategies

9.19 Ultragenyx Pharmaceutical
9.19.1 Quick Facts
9.19.2 Company Overview
9.19.3 Product Portfolio
9.19.4 Business Strategies

9.20 uniQure
9.20.1 Quick Facts
9.20.2 Company Overview
9.20.3 Product Portfolio
9.20.4 Business Strategies

1. Global Hemophilia Market Research and Analysis by Product Type, 2026–2035 ($ Million) 

2. Global Clotting Factor Replacement Therapy Market Research and Analysis by Region, 2026–2035 ($ Million) 

3. Global Extended Half-Life (EHL) Factor Products Market Research and Analysis by Region, 2026–2035 ($ Million) 

4. Global Non-Factor Replacement Therapy Market Research and Analysis by Region, 2026–2035 ($ Million) 

5. Global Gene Therapy Market Research and Analysis by Region, 2026–2035 ($ Million) 

6. Global Hemophilia Market Research and Analysis by Technology Platform, 2026–2035 ($ Million) 

7. Global Recombinant DNA Technology Market Research and Analysis by Region, 2026–2035 ($ Million) 

8. Global Plasma Fractionation Technology Market Research and Analysis by Region, 2026–2035 ($ Million) 

9. Global Fc Fusion / PEGylation (Half-life Extension) Market Research and Analysis by Region, 2026–2035 ($ Million) 

10. Global RNA Interference (RNAi) Market Research and Analysis by Region, 2026–2035 ($ Million) 

11. Global Gene Transfer (AAV Vectors) Market Research and Analysis by Region, 2026–2035 ($ Million) 

12. Global Hemophilia Market Research and Analysis by End User, 2026–2035 ($ Million) 

13. Global Hemophilia Market for Hospitals & Hemophilia Treatment Centers (HTCs) Research and Analysis by Region, 2026–2035 ($ Million) 

14. Global Hemophilia Market for Specialty Clinics Research and Analysis by Region, 2026–2035 ($ Million) 

15. Global Hemophilia Market for Homecare Settings Research and Analysis by Region, 2026–2035 ($ Million) 

16. Global Hemophilia Market Research and Analysis by Region, 2026–2035 ($ Million) 

17. North America Hemophilia Market Research and Analysis by Country, 2026–2035 ($ Million) 

18. North America Hemophilia Market Research and Analysis by Product Type, 2026–2035 ($ Million) 

19. North America Hemophilia Market Research and Analysis by Technology Platform, 2026–2035 ($ Million) 

20. North America Hemophilia Market Research and Analysis by End User, 2026–2035 ($ Million) 

21. Europe Hemophilia Market Research and Analysis by Country, 2026–2035 ($ Million) 

22. Europe Hemophilia Market Research and Analysis by Product Type, 2026–2035 ($ Million) 

23. Europe Hemophilia Market Research and Analysis by Technology Platform, 2026–2035 ($ Million) 

24. Europe Hemophilia Market Research and Analysis by End User, 2026–2035 ($ Million) 

25. Asia-Pacific Hemophilia Market Research and Analysis by Country, 2026–2035 ($ Million) 

26. Asia-Pacific Hemophilia Market Research and Analysis by Product Type, 2026–2035 ($ Million) 

27. Asia-Pacific Hemophilia Market Research and Analysis by Technology Platform, 2026–2035 ($ Million) 

28. Asia-Pacific Hemophilia Market Research and Analysis by End User, 2026–2035 ($ Million) 

29. Rest of the World Hemophilia Market Research and Analysis by Region, 2026–2035 ($ Million) 

1. Global Hemophilia Market Share by Product Type, 2026 Vs 2035 (%) 

2. Global Clotting Factor Replacement Therapy Market Share by Region, 2026 Vs 2035 (%) 

3. Global Extended Half-Life (EHL) Factor Products Market Share by Region, 2026 Vs 2035 (%) 

4. Global Non-Factor Replacement Therapy Market Share by Region, 2026 Vs 2035 (%) 

5. Global Gene Therapy Market Share by Region, 2026 Vs 2035 (%) 

6. Global Hemophilia Market Share by Technology Platform, 2026 Vs 2035 (%) 

7. Global Recombinant DNA Technology Market Share by Region, 2026 Vs 2035 (%) 

8. Global Plasma Fractionation Technology Market Share by Region, 2026 Vs 2035 (%) 

9. Global Fc Fusion / PEGylation (Half-life Extension) Market Share by Region, 2026 Vs 2035 (%) 

10. Global RNA Interference (RNAi) Market Share by Region, 2026 Vs 2035 (%) 

11. Global Gene Transfer (AAV Vectors) Market Share by Region, 2026 Vs 2035 (%) 

12. Global Hemophilia Market Share by End User, 2026 Vs 2035 (%) 

13. Global Hemophilia Market for Hospitals & Hemophilia Treatment Centers (HTCs) Share by Region, 2026 Vs 2035 (%) 

14. Global Hemophilia Market for Specialty Clinics Share by Region, 2026 Vs 2035 (%) 

15. Global Hemophilia Market for Homecare Settings Share by Region, 2026 Vs 2035 (%) 

16. Global Hemophilia Market Share by Region, 2026 Vs 2035 (%) 

17. US Hemophilia Market Size, 2026–2035 ($ Million) 

18. Canada Hemophilia Market Size, 2026–2035 ($ Million) 

19. UK Hemophilia Market Size, 2026–2035 ($ Million) 

20. France Hemophilia Market Size, 2026–2035 ($ Million) 

21. Germany Hemophilia Market Size, 2026–2035 ($ Million) 

22. Italy Hemophilia Market Size, 2026–2035 ($ Million) 

23. Spain Hemophilia Market Size, 2026–2035 ($ Million) 

24. Russia Hemophilia Market Size, 2026–2035 ($ Million) 

25. India Hemophilia Market Size, 2026–2035 ($ Million) 

26. China Hemophilia Market Size, 2026–2035 ($ Million) 

27. Japan Hemophilia Market Size, 2026–2035 ($ Million) 

28. South Korea Hemophilia Market Size, 2026–2035 ($ Million) 

29. Australia & New Zealand Hemophilia Market Size, 2026–2035 ($ Million) 

30. ASEAN Hemophilia Market Size, 2026–2035 ($ Million) 

31. Middle East & Africa Hemophilia Market Size, 2026–2035 ($ Million)

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The market was valued at $13.11 billion in 2025 and is projected to reach $20.45 billion by 2035.
The market is expected to grow at a CAGR of 4.5% between 2026 and 2035.
Clotting factor replacement therapy dominates due to its widespread clinical adoption.
North America leads due to advanced healthcare infrastructure and high treatment accessibility.
Gene therapy is growing fastest due to advancements in genetic treatment technologies.